ARTICLE | Clinical News
Kosan preclinical data
September 19, 2005 7:00 AM UTC
In dogs, KOS-2187, a second-generation erythromycin-derived motilin agonist, led to high oral bioavailability and significantly accelerated gastric emptying compared with placebo. In vitro, KOS-2187 ...